Caribou Biosciences (CRBU) EBIAT: 2020-2025
Historic EBIAT for Caribou Biosciences (CRBU) over the last 6 years, with Sep 2025 value amounting to -$27.5 million.
- Caribou Biosciences' EBIAT rose 20.57% to -$27.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$157.1 million, marking a year-over-year decrease of 6.09%. This contributed to the annual value of -$149.1 million for FY2024, which is 46.08% down from last year.
- Latest data reveals that Caribou Biosciences reported EBIAT of -$27.5 million as of Q3 2025, which was up 49.08% from -$54.1 million recorded in Q2 2025.
- In the past 5 years, Caribou Biosciences' EBIAT ranged from a high of -$10.0 million in Q3 2023 and a low of -$54.1 million during Q2 2025.
- Its 3-year average for EBIAT is -$33.9 million, with a median of -$34.7 million in 2024.
- As far as peak fluctuations go, Caribou Biosciences' EBIAT crashed by 664.48% in 2021, and later skyrocketed by 62.46% in 2023.
- Over the past 5 years, Caribou Biosciences' EBIAT (Quarterly) stood at -$18.5 million in 2021, then tumbled by 46.05% to -$27.0 million in 2022, then decreased by 27.85% to -$34.5 million in 2023, then decreased by 2.85% to -$35.5 million in 2024, then grew by 20.57% to -$27.5 million in 2025.
- Its EBIAT was -$27.5 million in Q3 2025, compared to -$54.1 million in Q2 2025 and -$40.0 million in Q1 2025.